Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24540771 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2CYP1A2NPSR1L3MBTL1IL1B | |
| SCHEMBL24540772 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2CYP1A2NPSR1L3MBTL1IL1B | |
| SCHEMBL24541159 | 0.88 | PDE3B (0.34) | SCN9AKCNH2SCN5A | |
| SCHEMBL24541160 | 0.88 | PDE3B (0.34) | SCN9AKCNH2SCN5A | |
| SCHEMBL24541161 | 0.88 | PDE3B (0.34) | SCN9AKCNH2SCN5A | |
| SCHEMBL24540747 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL24540735 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL24540736 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL24541090 | 0.82 | CHRNB2 (0.32) | — | |
| SCHEMBL24541089 | 0.82 | CHRNB2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | SMN1; SMN2 2221/4885CYP1A2 2983/4885NPSR1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.